Form 4: Madrigal Pharmaceuticals CMO Executes Stock Sale

Chief Medical Officer David Soergel sold 1,042 shares of Madrigal Pharmaceuticals common stock via a Rule 10b5-1 plan.

Summary

• David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, sold 1,042 shares of common stock.
• The transaction occurred on June 1, 2026, at a price of $495.74 per share.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on March 2, 2026.
• Following the transaction, the reporting person retains beneficial ownership of 10,033 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small portion of the executive's total holdings.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this specific filing.

Future Outlook

Not applicable as this is a routine disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common practice in the biotechnology sector and generally does not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-arranged plan.

Next Steps

• None

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Insider Trading, Form 4, Biotech, Executive Stock Sale